查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
CAR-T 細胞治療市場：按藥物類型、按適應症、按最終用戶、按國家、按地區 - 行業分析、市場規模、市場份額、預測 2023-2030
市場調查報告書
商品編碼
1304643

CAR-T 細胞治療市場：按藥物類型、按適應症、按最終用戶、按國家、按地區 - 行業分析、市場規模、市場份額、預測 2023-2030

CAR T-cell therapy Market with COVID-19 Impact Analysis, By Drug Type, By Indication, By End User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2023-2030
出版日期: | 出版商: AnalystView Market Insights | 英文 288 Pages | 商品交期: 2-3個工作天內

價格

報告要點

2022年CAR-T細胞治療市場規模將達到23.084億美元，2023年至2030年復合年增長率為21.8%

CAR-T 細胞治療市場-市場動態：

癌症患病率上升預計將推動市場需求

癌症患病率的增加預計將主導 CAR-T 細胞治療市場的增長。嵌合抗原受體 CAR-T 細胞療法是癌症免疫細胞療法的一個進步的新支柱。目前可用的 CAR-T 細胞療法是針對每位患者定制的。據世界衛生組織 (WHO) 稱，癌症是全球頭號死亡原因，到 2020 年，癌症將導致約 1000 萬人死亡，即每 6 人中就有 1 人死於癌症。僅在美國，目前就有 1,000 多名患者正在接受 CAR-T 細胞治療，並且已經啟動了幾項研究，以觀察對應答者的長期影響。新型生物療法研究的進展以及生物製劑可用性和安全性的提高預計將為 CAR-T 細胞療法市場提供增長機會。嚴重危及生命的毒性、適度的抗腫瘤活性、抗原逃逸、運輸限制和腫瘤侵襲限制是限制市場增長的因素。

CAR-T 細胞治療市場關鍵洞察：

  • 根據我們的研究分析師分享的分析，預計在預測期內（2023-2030年），全球紙袋包裝市場的年復合增長率約為21.8%。
  • 由於人們對可持續增長的認識不斷增強，紙袋包裝行業預計將以驚人的速度增長
  • 在藥物類型細分中，TisagenRecuCel 藥物類型預計將在 2022 年佔據最大的市場份額
  • 有跡象表明，淋巴瘤是 2022 年的主要類型。
  • 從最終用戶來看，酒店業將成為 2022 年的主導類型。
  • 按地區劃分，北美是2022年的主要收入來源。

CAR-T 細胞治療市場細分分析：

全球 CAR-T 細胞治療市場根據藥物類型、適應症、最終用戶和地區進行細分。

按藥物類型劃分，市場分為 Ciloleucel、Tisagenlecleucel、Axicabtagene、Autoleucel、Brexucabtagene 等。Tisagenlecleucel 藥物類型在市場上佔據主導地位。最近批准的產品包括 Tisagenleucel，這是一種 CAR T 療法，被批准用於使用患者的自體 T 細胞治療 B 細胞急性淋巴細胞白血病 (B-ALL)。隨著 Tissagenre-Clucel 現在成為 B-ALL 的護理標準，能夠準確監測患者的 CAR T 細胞在臨床上勢在必行。

市場按適應症分為六類：慢性淋巴細胞白血病（CLL）、多發性骨髓瘤（MM）、淋巴瘤、急性淋巴細胞白血病等。該療法是一種高度專業化的治療方法，通過基因改造患者自身的 T 細胞來攻擊癌症。

市場按最終用戶分為六類：醫院和癌症治療中心。酒店業是 2022 年的主導類型。擁有 CAR-T 細胞治療項目的專業癌症中心和醫院具備充分的條件來實施這種療法。這些醫院擁有基礎設施、設施和經驗豐富的醫療專業人員，可以提供安全有效的護理。

CAR-T細胞治療市場-地理洞察：

從地理上看，該市場遍布北美、拉丁美洲、歐洲、亞太地區、中東和非洲。這些區域根據我們開展業務的國家/地區進一步細分。癌症負擔的增加以及CAR-T細胞療法研發的增加預計將推動北美CAR-T細胞療法市場的增長。據美國癌症協會預測，2021年美國新增癌症病例和死亡人數預計將增至190萬例，癌症死亡人數將達到60萬人，預計為8570人。由於與嵌合抗原受體 CAR-T 細胞療法相關的產品批准不斷增加，歐洲和亞太地區預計將推動 CAR-T 細胞療法市場的顯著增長。

CAR-T細胞治療市場-競爭格局：

公司正在大力投資研發，以加強細胞系開發技術、開發新產品並探索新的治療應用。這些公司提供廣泛的服務，包括合同研究、合同製造、臨床試驗服務以及為生物製藥公司提供的其他支持服務。一家開發平台技術以提高 CAR-T 細胞療法安全性的生物技術公司向 Alacrity 尋求全面的競爭格局研究，以更好地了解當前 CAR-T 細胞療法領域。該公司希望了解正在開發的主要 CAR-T 細胞療法的公司概況、該領域當前的挑戰、其他公司採用的解決方案以及交易狀態。這將作為業務戰略和產品開發戰略的指南，以最大限度地發揮自身技術的價值。

最近的發展

Johnson & Johnson旗下 Janssen Pharma 2023 年 5 月 2 日宣布已達成全球合作和許可，開發下一代嵌合抗原受體 CAR-T 細胞療法，用於治療 B 細胞惡性腫瘤與Cellular Biomedicine Group Inc. (CBMG ) 就製造和商業化達成協議。

調查的主要特點

本研究報告以2022年為基準年，提供了CAR-T細胞治療市場的市場規模、複合年增長率（CAGR%）、估計和預測（2023-2030年）。

該研究報告為客戶提供了對 CAR-T 細胞治療市場最新發展的深入了解。

該研究報告闡明了不同細分市場/國家的潛在增長機會，並描述了 CAR-T 細胞治療市場有吸引力的投資主張矩陣。

總體報告確定了 CAR-T 細胞治療市場的新興投資機會、現有企業面臨的挑戰以及持續增長動力。

研究範圍詳細討論了 COVID-19 對 CAR-T 細胞療法市場規模、預測、複合年增長率和市場動態的影響。它還涵蓋了對新冠疫情後 CAR-T 細胞治療市場的詳細見解。

為了向本報告的用戶提供對 CAR-T 細胞治療市場的全面了解，我們還包括了 CAR-T 細胞治療市場的競爭格局和關鍵創新者分析。

該研究涵蓋了基於市場規模、增長率和吸引力對所有行業領域進行基準測試的增長前景映射分析。

提供主要市場進入者的詳細公司簡介，幫助您了解 CAR-T 細胞治療市場運營公司的財務信息和戰略舉措。

此外，報告還揭示了市場主要進入者不僅在全球層面而且在區域層面的重大收購和兼併、聯盟和合資企業、新產品推出、研發和區域擴張。

全球 CAR-T 細胞治療市場報告主要面向該行業的各個利益相關者，如供應商、投資者、新進入者、分銷商和財務分析師。

目錄

第一章 CAR-T細胞治療市場概況

  • 調查範圍
  • 預計上市年限

第二章執行摘要

  • 市場細分
  • 競爭考慮

第三章 CAR-T細胞療法主要市場趨勢

  • CAR-T細胞治療市場驅動因素
  • CAR-T細胞治療市場製約因素
  • CAR-T細胞療法的市場機會
  • CAR-T細胞治療市場未來趨勢

第四章 CAR-T細胞治療行業概況

  • PEST分析
  • 波特五力分析
  • 繪製增長前景
  • 監管框架分析

第五章 CAR-T細胞治療市場：COVID-19的影響分析

  • COVID-19 之前的影響分析
  • COVID-19 後的影響分析

第六章 CAR-T細胞治療市場格局

  • 2022 年 CAR-T 細胞療法市場份額分析
  • 主要製造商的細分數據
    • 已成立公司分析
    • 啟動分析

7. CAR-T細胞治療市場——按藥物類型

  • 概述
    • 按藥品類型劃分的細分市場份額分析
    • Axicabutagen/Siloleucel
    • Tisagen Reclusell
    • brexcabutagen autoleucel
    • 其他

8. CAR-T細胞治療市場-按適應症分類

  • 概述
    • 按指標劃分的細分市場份額分析
    • 淋巴瘤
    • 急性淋巴細胞白血病
    • 慢性淋巴細胞白血病（CLL）
    • 多發性骨髓瘤 (MM)
    • 其他

9. CAR-T細胞治療市場-按最終用戶劃分

  • 概述
    • 按最終用戶劃分的細分市場份額分析
    • 醫院
    • 癌症治療中心

第10章CAR-T細胞治療市場按地區

  • 介紹
  • 北美
    • 概述
    • 北美CAR-T細胞療法領先製造商
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 歐洲領先的 CAR-T 細胞療法製造商
    • 德國
    • 意大利
    • 英國
    • 法國
    • 俄羅斯
    • 荷蘭
    • 瑞典
    • 波蘭
    • 其他
  • 亞太地區 (APAC)
    • 概述
    • 亞太區領先的CAR-T細胞療法製造商
    • 印度
    • 中國
    • 日本
    • 韓國
    • 澳大利亞
    • 泰國
    • 印度尼西亞
    • 菲律賓
    • 其他
  • 拉丁美洲
    • 概述
    • 拉丁美洲 CAR-T 細胞療法領先製造商
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 其他
  • 中東和非洲
    • 概述
    • 中東和非洲領先的 CAR-T 細胞療法製造商
    • 沙特阿拉伯
    • 阿拉伯聯合酋長國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • 其他

第十一章重點廠商分析-CAR-T細胞治療行業

  • 比賽儀表板
  • 公司簡介
    • Johnson & Johnson Services, Inc.
    • ALLOGENE THERAPEUTICS
    • Lonza
    • Aurora Biopharma
    • Cartesian Therapeutics, Inc.
    • Novartis
    • Bristol-Myers Squibb company
    • Gilead Sciences
    • Curocell Inc
    • JW Therapeutics

第十二章 分析師的全面看法

Product Code: ANV1382

REPORT HIGHLIGHT

CAR T-cell therapy Market size was valued at USD 2,308.4 million in 2022, expanding at a CAGR of 21.8% from 2023 to 2030.

Chimeric antigen receptor (CAR)-T cell therapy has been revolutionary as it has produced remarkably effective and durable clinical responses. CAR T-cell therapy is used to treat certain blood cancers, and it is being studied in the treatment of other types of cancer. Also called chimeric antigen receptor T-cell therapy. These therapies do not require aggressive chemotherapy, and unless there is an elevation in cytokines following infusion, patients receiving CAR T-cells do not typically require immunosuppression. The advantage of chimeric antigen receptor (CAR) T-cell therapy is that it is administered in a single infusion, requiring a shorter treatment time. Also, It Improves immunogenic memory, which provides continuous surveillance to treat local and distant metastatic lesions. The main benefit of CAR-T therapy is that it can be curative for people whose blood cancer has not responded to other types of treatments. While CAR-T therapy is often considered a last resort, it is often an effective one.

CAR T-cell therapy Market- Market Dynamics:

The increasing prevalence of cancer is expected to propel market demand

The increasing prevalence of cancer is expected to dominate the growth of the CAR T-cell therapy Market. Chimeric antigen receptor (CAR)-T cell therapy is a progressive new pillar in immune cell therapy for cancer. Currently, available CAR T-cell therapies are customized for each individual patient. According to World health organization, Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths. In the United States alone, well over 1000 patients have now received CAR-T cells, and several studies have opened looking at the long-term effects in responders. Advancing research on novel biotherapies and increasing the supply and safety of biologics are the factors that are expected to provide growth opportunities for the CAR T-cell therapy market. The severe life-threatening toxicities, modest anti-tumor activity, antigen escape, restricted trafficking, and limited tumor infiltration are the factors which restrict the growth of market.

CAR T-cell Therapy Market- Key Insights:

  • As per the analysis shared by our research analyst, the global CAR T-cell therapy market is estimated to grow annually at a CAGR of around 21.8% over the forecast period (2023-2030)
  • Based on Drug Type segmentation, Tisagenlecleucel drug type was predicted to show maximum market share in the year 2022
  • Based on Indication segmentation, Lymphoma was the leading type in 2022
  • Based on End-User segmentation, Hospitals was the leading type in 2022
  • On the basis of region, North America was the leading revenue generator in 2022

CAR T-cell Therapy Market- Segmentation Analysis:

The Global CAR T-cell therapy Market is segmented on the basis of Drug Type, Indication, End User, and Region.

The market is divided into five categories based on Drug Type: Ciloleucel, Tisagenlecleucel, Axicabtagene, Autoleucel, Brexucabtagene, and Others. Tisagenlecleucel drug type dominates the market. One such recently licensed product has been Tisagenlecleucel, a CAR T therapy approved for the treatment of B-cell acute lymphoblastic leukemia (B-ALL) using autologous T cells from the patient. Since Tisagenlecleucel is now a standard of care treatment for B-ALL, it is clinically essential to be able to accurately monitor these CAR T cells in patients.

The market is divided into six categories based on Indication: Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), Lymphoma, Acute Lymphocytic Leukemia, and Others. dominates the market and is likely to maintain its dominance during the forecast period. It is a highly specialized therapy that involves genetically modifying a patient's own T cells to attack their cancer.

The market is divided into six categories based on End -User: Hospitals and Cancer Treatment Centers. Hospitals are the leading type in 2022. Hospitals with specialized cancer centers or designated CAR T-cell therapy programs are equipped to handle the administration of this therapy. They have the infrastructure, facilities and experienced health professionals to provide safe and effective treatment.

CAR T-cell therapy Market- Geographical Insights:

Geographically, this market is widespread into the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business. The increasing burden of cancer and the rise in research and development to develop CAR T-cell therapy is expected to drive the growth of CAR T-cell therapy Market in north America. According to the American cancer society, number of new cancer cases and deaths in 2021 (In 2021, there will be an estimated 1.9 million new cancer cases diagnosed and 608,570 cancer deaths in the United States. Europe and Asia Pacific are expected to propel significant growth in CAR T-cell therapy Market, due to the Growing Product Approvals Associated with Chimeric antigen receptor (CAR)-T cell therapy.

CAR T-cell therapy Market- Competitive Landscape:

Companies invest heavily in research and development to enhance their cell line development technologies, develop new products, and explore novel therapeutic applications. These players offer a wide range of services, including contract research, contract manufacturing, clinical trial services, and other support services for biopharmaceutical companies. A biotech company developing a platform technology to improve the safety of CAR T-cell therapies asked Alacrity to conduct a comprehensive competitive landscape to better understand the current CAR T-cell therapy space. The company wanted to understand the product profiles of top CAR T-cell therapies in development, current challenges in the field and solutions other companies are employing, as well as the deals landscape. This would help guide their business and product development strategy to maximize the value of their technology.

Recent Developments:

In May 2, 2023 -one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced nowadays that it has entered into a worldwide collaboration and license agreement with Cellular Biomedicine Group Inc. (CBMG) to develop, manufacture and commercialize next-generation chimeric antigen receptor (CAR) T-cell therapies for the treatment of B-cell malignancies.

Key features of the study:

This proposed research study on CAR T-cell therapy market provides market size (US$ million), compound annual growth rate (CAGR %) and forecast estimation (2023-2030), considering 2022 as the base year

The report provides the client the latest up-to-date and trending insights about the CAR T-cell therapy market.

The research report elucidates potential growth opportunities across different segments/countries and explains attractive investment proposition matrix for CAR T-cell therapy market

The overall report identifies new investment opportunities, challenges faced by established players, and growth factors to sustain in the CAR T-cell therapy market

Impact of COVID-19 on CAR T-cell therapy market size, forecast, CAGR, and market dynamics are discussed in detail under the research scope. Detailed insight on CAR T-cell therapy market post-COVID will also be covered.

In order to give the users of this report a comprehensive view on the CAR T-cell therapy market, we have also included competitive landscape and key innovator analysis for the CAR T-cell therapy market.

The study encompasses a growth prospect mapping analysis, wherein all the industry segments are benchmarked based on their market size, growth rate and attractiveness.

The report offers detailed company profiling featuring major market participants which will help users to understand their financial information and strategic initiatives of players operating in the CAR T-cell therapy market.

In addition, the report also unveil the important acquisitions & mergers, collaborations & joint ventures, new launch, research & development, regional expansion of major participants involved in the market on global as well as regional level.

The global CAR T-cell therapy market report primarily caters to various stakeholders in this industry including suppliers, investors, new entrants, distributors, and financial analysts

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL CAR T-CELL THERAPY MARKET KEY PLAYERS

  • Johnson & Johnson Services, Inc.
  • ALLOGENE THERAPEUTICS
  • Lonza
  • Aurora Biopharma
  • Cartesian Therapeutics, Inc.
  • Novartis
  • Bristol-Myers Squibb company
  • Gilead Sciences
  • Curocell Inc
  • JW Therapeutics

GLOBAL CAR T-CELL THERAPY MARKET, BY DRUG TYPE

  • Axicabtagene Ciloleucel
  • Tisagenlecleucel
  • Brexucabtagene Autoleucel
  • Others

GLOBAL CAR T-CELL THERAPY MARKET, BY INDICATION

  • Lymphoma
  • Acute Lymphocytic Leukemia
  • Chronic Lymphocytic Leukemia (CLL)
  • Multiple Myeloma (MM)
  • Others

GLOBAL CAR T-CELL THERAPY MARKET, BY END-USER

  • Hospitals
  • Cancer Treatment Centers

GLOBAL CAR T-CELL THERAPY MARKET, BY REGION

  • North America
    • The U.S.
    • Canada
  • Europe
    • Germany
    • France
    • Italy
    • Spain
    • United Kingdom
    • Russia
    • Netherlands
    • Sweden
    • Poland
    • Rest of Europe
  • Asia Pacific
    • India
    • China
    • South Korea
    • Japan
    • Australia
    • Thailand
    • Indonesia
    • Philippines
    • Rest of APAC
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Colombia
    • Rest of LATAM
  • The Middle East and Africa
    • Saudi Arabia
    • United Arab Emirates
    • Israel
    • Turkey
    • Algeria
    • Egypt
    • Rest of MEA

Table of Contents

1. CAR T-Cell Therapy Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. CAR T-Cell Therapy Market Snippet by Drug Type
    • 2.1.2. CAR T-Cell Therapy Market Snippet by Indication
    • 2.1.3. CAR T-Cell Therapy Market Snippet by End User
    • 2.1.4. CAR T-Cell Therapy Market Snippet by Country
    • 2.1.5. CAR T-Cell Therapy Market Snippet by Region
  • 2.2. Competitive Insights

3. CAR T-Cell Therapy Key Market Trends

  • 3.1. CAR T-Cell Therapy Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. CAR T-Cell Therapy Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. CAR T-Cell Therapy Market Opportunities
  • 3.4. CAR T-Cell Therapy Market Future Trends

4. CAR T-Cell Therapy Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. CAR T-Cell Therapy Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. CAR T-Cell Therapy Market Landscape

  • 6.1. CAR T-Cell Therapy Market Share Analysis, 2022
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. CAR T-Cell Therapy Market - By Drug Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Drug Type, 2022 & 2030 (%)
    • 7.1.2. Axicabtagene Ciloleucel
    • 7.1.3. Tisagenlecleucel
    • 7.1.4. Brexucabtagene Autoleucel
    • 7.1.5. Others

8. CAR T-Cell Therapy Market - By Indication

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Indication, 2022 & 2030 (%)
    • 8.1.2. Lymphoma
    • 8.1.3. Acute Lymphocytic Leukemia
    • 8.1.4. Chronic Lymphocytic Leukemia (CLL)
    • 8.1.5. Multiple Myeloma (MM)
    • 8.1.6. Others

9. CAR T-Cell Therapy Market - By End User

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By End User, 2022 & 2030 (%)
    • 9.1.2. Hospitals
    • 9.1.3. Cancer Treatment Centers

10. CAR T-Cell Therapy Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2022 & 2030 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. CAR T-Cell Therapy Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. CAR T-Cell Therapy Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.3.8. Italy
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.8.3. Italy Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.3.8.4. Italy Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.3.8.5. Italy Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.3.9. United Kingdom
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.9.3. United Kingdom Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.3.9.4. United Kingdom Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.3.9.5. United Kingdom Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.3.10. France
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.10.3. France Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.3.10.4. France Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.3.10.5. France Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.3.11. Russia
      • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.11.2. Russia Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.3.11.3. Russia Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.3.11.4. Russia Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.3.12. Netherlands
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.12.2. Netherlands Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.3.12.3. Netherlands Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.3.12.4. Netherlands Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.13.2. Sweden Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.3.14. Poland
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.14.2. Poland Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.3.14.3. Poland Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.3.14.4. Poland Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.3.15. Rest of Europe
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.3.15.5. Rest of the Europe Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. CAR T-Cell Therapy Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. CAR T-Cell Therapy Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. CAR T-Cell Therapy Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Drug Type, 2018 - 2030 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Indication, 2018 - 2030 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By End User, 2018 - 2030 (US$ Million)

11. Key Vendor Analysis- CAR T-Cell Therapy Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. Johnson & Johnson Services, Inc.
    • 11.2.2. ALLOGENE THERAPEUTICS
    • 11.2.3. Lonza
    • 11.2.4. Aurora Biopharma
    • 11.2.5. Cartesian Therapeutics, Inc.
    • 11.2.6. Novartis
    • 11.2.7. Bristol-Myers Squibb company
    • 11.2.8. Gilead Sciences
    • 11.2.9. Curocell Inc
    • 11.2.10. JW Therapeutics

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us

List of Tables

  • TABLE List of data sources
  • TABLE Market drivers; Impact Analysis
  • TABLE Market restraints; Impact Analysis
  • TABLE CAR T-Cell Therapy Market: Drug Type Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Drug Type
  • TABLE Global CAR T-Cell Therapy Market, by Drug Type 2018-2030 (USD Million)
  • TABLE CAR T-Cell Therapy Market: Indication Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Indication
  • TABLE Global CAR T-Cell Therapy Market, by Indication 2018-2030 (USD Million)
  • TABLE CAR T-Cell Therapy Market: End User Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by End User
  • TABLE Global CAR T-Cell Therapy Market, by End User 2018-2030 (USD Million)
  • TABLE CAR T-Cell Therapy Market: Regional snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Region
  • TABLE Global CAR T-Cell Therapy Market, by Region 2018-2030 (USD Million)
  • TABLE North America CAR T-Cell Therapy Market, by Country, 2018-2030 (USD Million)
  • TABLE North America CAR T-Cell Therapy Market, by Drug Type, 2018-2030 (USD Million)
  • TABLE North America CAR T-Cell Therapy Market, by Indication, 2018-2030 (USD Million)
  • TABLE North America CAR T-Cell Therapy Market, by End User, 2018-2030 (USD Million)
  • TABLE Europe CAR T-Cell Therapy Market, by Country, 2018-2030 (USD Million)
  • TABLE Europe CAR T-Cell Therapy Market, by Drug Type, 2018-2030 (USD Million)
  • TABLE Europe CAR T-Cell Therapy Market, by Indication, 2018-2030 (USD Million)
  • TABLE Europe CAR T-Cell Therapy Market, by End User, 2018-2030 (USD Million)
  • TABLE Asia Pacific CAR T-Cell Therapy Market, by Country, 2018-2030 (USD Million)
  • TABLE Asia Pacific CAR T-Cell Therapy Market, by Drug Type, 2018-2030 (USD Million)
  • TABLE Asia Pacific CAR T-Cell Therapy Market, by Indication, 2018-2030 (USD Million)
  • TABLE Asia Pacific CAR T-Cell Therapy Market, by End User, 2018-2030 (USD Million)
  • TABLE Latin America CAR T-Cell Therapy Market, by Country, 2018-2030 (USD Million)
  • TABLE Latin America CAR T-Cell Therapy Market, by Drug Type, 2018-2030 (USD Million)
  • TABLE Latin America CAR T-Cell Therapy Market, by Indication, 2018-2030 (USD Million)
  • TABLE Latin America CAR T-Cell Therapy Market, by End User, 2018-2030 (USD Million)
  • TABLE Middle East and Africa CAR T-Cell Therapy Market, by Country, 2018-2030 (USD Million)
  • TABLE Middle East and Africa CAR T-Cell Therapy Market, by Drug Type, 2018-2030 (USD Million)
  • TABLE Middle East and Africa CAR T-Cell Therapy Market, by Indication, 2018-2030 (USD Million)
  • TABLE Middle East and Africa CAR T-Cell Therapy Market, by End User, 2018-2030 (USD Million)